News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Börse Express Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Maxim Group has reiterated its Buy rating for Moleculin Biotech (MBRX.US) but has reduced the target price for the stock to $2. This adjustment reflects a revised outlook on the company's valuation while maintaining a positive long-term perspective.
Royal Bank of Canada upgraded Krystal Biotech (NASDAQ:KRYS) to a "moderate buy" rating, aligning with a generally bullish analyst consensus. The company, which has a market capitalization of $9.83 billion, recently reported quarterly earnings that beat expectations but revenue that slightly missed. Insider selling …
Krystal Biotech (KRYS) Director Dino Rossi sold 25,000 shares of the company on August 14, 2026, for approximately $8.23 million, reducing his direct ownership to 50,000 shares. This sale continues a trend of insider selling over the past year, with no insider buys reported, …
Wall Street Zen has downgraded Fortress Biotech (NASDAQ:FBIO) from a "strong-buy" to a "hold" rating. The stock currently holds an average "Hold" rating among analysts with a consensus price target of $17.00. Fortress Biotech recently reported stronger-than-expected quarterly earnings, with EPS of -$0.08 and …
Wall Street Zen upgraded Puma Biotechnology (NASDAQ:PBYI) from a "buy" to a "strong-buy" rating, despite the broader analyst consensus remaining "hold" with a $6.00 price target. The company reported strong quarterly earnings, beating EPS and revenue estimates, though insiders have sold a significant number …
Krystal Biotech (KRYS.US) Director, Daniel Meyer, sold 84,200 shares of common stock on August 13, 2026, for a total of $8.23 million. The shares were sold at an average price of $97.75. Following this transaction, Meyer directly owns 10,000 shares of the company.
Moleculin Biotech (MBRX) reported a net loss of $7.6 million for Q2 2026, with a significant improvement in loss per share, narrowing to $1.40 from $12.25 in Q2 2025. The company, focused on therapeutic candidates for tumors and viruses, generated no revenue but continued …
Perceptive Advisors and its related entities have filed an updated 13D/A, disclosing a 9.1% beneficial ownership in Nautilus Biotechnology, Inc. (NAUT), totaling 11,634,211 shares. This ownership is primarily held by Perceptive Life Sciences Master Fund, Ltd. and C2 Life Sciences LLC, with Perceptive Advisors …
This article reports on a Form 144 SEC filing by Krystal Biotech, Inc. (KRYS) on August 14, 2026. The filing indicates a proposed sale of 25,000 shares of common stock with an aggregate market value of $8,306,750, acquired from the public market on September …
Moleculin Biotech (NASDAQ: MBRX) is holding its 2026 annual shareholder meeting on October 9, 2026, where key proposals include electing directors, ratifying the independent auditor, and approving an amendment to the 2024 Equity Incentive Plan to increase authorized shares. Shareholders will also vote on …
ARCH venture funds and related entities, along with several individual managers, have reported an updated collective beneficial ownership of 15.3% in Sana Biotechnology (SANA) common stock as of June 30, 2026. This amounts to 45,860,681 shares based on 299,360,637 shares outstanding. Robert Nelsen, a …
This article is a Schedule 13G/A filing for Sana Biotechnology. It indicates an amendment to a previous filing, typically related to significant ownership of the company's stock by an institutional investor or beneficial owner. This is a standard regulatory disclosure.
Sana Biotechnology (NASDAQ:SANA) shares dropped 5.3% to $3.4750 on Friday, with trading volume significantly below average. Despite the dip, analyst sentiment is mixed but leans positive, with an average target price of $9.50, although one analyst recently downgraded the stock to "Sell." The company …
Alvotech (Z45) released its Q2 2023 earnings report, showing an EPS beat of +€0.07 with an actual EPS of -€0.05 against a consensus of -€0.12. However, the company missed revenue expectations significantly, reporting €3.81M against an expected €36.49M. The earnings announcement was on August …
Krystal Biotech (KRYS) has further room for gains driven by Vyjuvek, its treatment for the rare blistering condition dystrophic epidermolysis bullosa, alongside international launches and growth across its gene therapy pipeline, RBC Capital said Friday in a report.Krystal's Silver Upgrade to read this MT …
Puma Biotechnology reported strong Q2 2026 financial results, with total revenue reaching $56.5 million, primarily driven by increased demand for NERLYNX. The company is now debt-free after repaying its Athyrium loan and has raised its full-year guidance for both product revenue and net income. …
Sana Biotechnology, Inc.'s average 12-month price target has been reduced slightly from $9.5 to $9.38 by 8 analysts, with individual forecasts ranging from $6 to $16 per share. Despite the cut, the new target still suggests a significant 155% potential upside based on the …
Search by ticker symbol or company name and select a result to open its chart.